Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
NuVasive (NUVA) Suffers From Macro Headwinds, Price Issue
by Zacks Equity Research
NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.
Intuitive Surgical (ISRG) Reports Mixed Preliminary Q4 Revenues
by Zacks Equity Research
Intuitive Surgical's (ISRG) revenue growth in the fourth quarter is driven by increase in procedure volume, partially offset by resurgence of COVID-19 in China.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Inogen (INGN) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its product sales.
UnitedHealth (UNH) Unit Ties Up to Boost Care in Two U.S. Regions
by Zacks Equity Research
UnitedHealth Group's (UNH) subsidiary Optum aims to advance organizational efficiencies of Owensboro Health and bring about better health outcomes in western Kentucky and southern Indiana.
PacBio's (PACB) Preliminary Q4 Revenues Dampened by Lower Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.
Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.
QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails
by Zacks Equity Research
The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.
Syneos Health (SYNH) to Launch Serplulimab With New Pact
by Zacks Equity Research
Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.
Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Here's Why Investors Should Buy Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
DexCom (DXCM) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its CGM sales.
QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen
by Zacks Equity Research
QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.
Here's Why You Should Retain Veradigm (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Veradigm (MDRX) owing to its strategic alliances.
Illumina (ILMN), Nashville Biosciences Partner With Amgen
by Zacks Equity Research
Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.
Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind
by Zacks Equity Research
Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.
Abbott's (ABT) New Launch to Boost Blood Donation Experience
by Zacks Equity Research
Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub (SDC) on continued strategic partnerships and expansion in the teledentistry space.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
LabCorp (LH) Oncology Arm Gains Traction, Margin Pressure Stays
by Zacks Equity Research
In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.
QuidelOrtho (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.
Baxter (BAX) Plans to Form Standalone Kidney Care Company
by Zacks Equity Research
Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.
Teladoc (TDOC) Unveils App to Simplify Whole-Person Care
by Zacks Equity Research
Teladoc Health (TDOC) launches a digital app that will provide a broad range of TDOC's services to cater to the whole-person health needs of members.